Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00003657

NCT00003657
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with a cancer that has been confirmed by a tissue sample (biopsy).
  • Your cancer has spread to other parts of the body or cannot be removed by surgery.
  • You may be responding to current treatment — the trial includes specific cancer types such as: ovarian cancer (stage IIIC/IV or returned/hard-to-treat), relapsed germ cell cancer, relapsed lymphoma, small cell lung cancer in partial or complete remission, sarcomas near or in complete remission after chemotherapy, stage IIIB non-small cell lung cancer responding to chemotherapy, bladder cancer, head and neck cancer, cancer of unknown origin, or other cancers without a standard curative treatment option (confirm with trial site for your specific cancer type).
  • You are between 18 and 55 years old (based on physical health age, not just calendar age).
  • You are in good general health and able to carry out normal daily activities with little or no limitation (performance status 0–1).
  • It has been more than 1 week since any surgery or radiation therapy.
  • It has been more than 3 weeks since your last chemotherapy.
  • You are willing and able to give informed consent to participate.
  • Your blood test results meet the required levels: white blood cell count at least 3,000, platelets at least 100,000, kidney function within acceptable range, liver function within acceptable range (confirm specific values with trial site).
  • Your kidneys are filtering blood at an adequate rate (creatinine clearance at least 60 cc/min).
  • Tests show no cancer currently in your bone marrow or brain.

Who may not be able to join:

  • You have a serious heart condition, including a heart attack within the last 6 months or heart failure that is not controlled.
  • You currently have an uncontrolled bacterial, viral, or fungal infection, or an active stomach/duodenal ulcer that has not been treated successfully.
  • You are pregnant.
  • You are unable to stop taking blood pressure medication for at least 24 hours before receiving the study drug Ethyol.
  • You have another serious medical or psychiatric condition that would prevent you from giving informed consent or safely receiving general anesthesia.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Dana-Farber Cancer Institute
Registry
clinicaltrials_gov
Start date
1 July 1998
Est. completion
1 November 2000

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percentage of Participants with Grade 2 or higher renal toxicities

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov